Latest news

Company that develops innovative blood sampling raises capital with Sciety

2020-11-24

NEW COMPANY AT SCIETY. Most blood sampling is still performed by qualified healthcare personnel at care facilities, but new technology…

Read more

Cartana is acquired by 10x Genomics for 425 MSEK

2020-09-11

PRESS RELEASE. The American biotechnology company 10x Genomics acquires the Swedish company Cartana, which was financed by the Sciety investment…

Read more
Cartana__39

The investment syndicate

Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.

Read more about the Sciety investment syndicate and membership

Sciety life science day 1

Services we offer

Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.

Find out more about our services

Cartana_Sciety

What our clients say

“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”

Malte Kühnemund,  CEO Cartana

More client testimonials

Investment areas

Biotechnology

From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.

Medical technology

From clinical validation phase to expansion phase.

Pharmacology

From late preclinical phase to Phase II clinical trials. All therapeutic areas.

Diagnostics

From clinical validation to expansion phase. All indications.

ICT in healthcare

From pilot phase to expansion phase. Value-enhancing healthcare.

Health tech

From early sales to expansion phase. Preventive health and medical services.

Current investment opportunities

Receive information about upcoming investment opportunities

Sign up to receive information about upcoming investment opportunities and invitations to investor lunches with the companies' executive management teams.

Selection of executed investments

Image showing a nanomolecular structure.

Synartro: 2

Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.

An enlarged image of nerve cells with nerve fibers, so-called axons.

PharmNovo

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

The Sciety syndicate invests in Synartro Synartro is developing a novel therapy for knee osteoarthritis.

Synartro: 1

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Cavis Technologies

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.